Does kinesiotaping can improve static stability of the knee after anterior cruciate ligament rupture? A randomized single-blind, placebo‐controlled trial

Table 2 Comparsion of outcome variables characterizing the measurement of the SP, SPAP variable at baseline and after application of KT

		Baseline	Post	X difference (95% CI)	p^a	ES^a
		X±SD	X±SD	X difference (95% CI)	p^a	ES^a
SP [mm]	Experimental	1107.3±288.8	927.8±295.9	-179.5 (1.81 to 2.01)	<0.001	0.61
	Placebo	1073.9±266.5	1033.1±289.2	-40.8 (1.45 to 2.56)	0.060	0.14
	p^b	0.638	0.043
	ES^b	0.11	0.36
SPAP [mm]	Experimental	818.3±238.4	622.4±254.8	-195.9 (2.05 to 2.91)	<0.001	0.79
	Placebo	702.4±219.3	698.1±217.5	-4.3 (1.01 to 3.01)	0.067	0.02
	p^b	0.464	0.039
	ES^b	0.50	0.32
SPML [mm]	Experimental	763.9±238.6	681.2±234.0	-82.7(2.21 to 3.34)	0.031	0.35
	Placebo	752.1±208.6	728.6±194.8	-63.5 (1.26 to 2.69)	0.221	0.11
	p^b	0.882	0.046
	ES^b	0.05	0.22
MV [mm/s]	Experimental	36.7±8.7	32.2±9.3	-4.5 (1.98 to 2.78)	0.039	0.49
	Placebo	37.3±±9.9	35.6±9.5	-1.7 (1.45 to 2.21)	0.089	0.17
	p^b	0.079	0.042
	ES^b	0.06	0.36
MVAP [mm/s]	Experimental	23.2±5.8	19.2±7.6	-4 (1.67 to 2.56)	0.043	0.59
	Placebo	23.8±7.4	22.2±7.9	-1.6 (1.75 to 3.01)	0.079	0.20
	p^b	0.096	0.039
	ES^b	0.09	0.38
MVML [mm/s]	Experimental	24.4±6.8	20.3±6.5	-4.1 (1.21 to 2.45)	0.031	0.61
	Placebo	25.1±6.4	23.1±6.2	-2 (0.92 to 3.42)	0.112	0.31
	p^b	0.065	0.024
	ES^b	0.10	0.44

Baseline the measurement before application of KT; Post the measurement after application of KT; SPthe total path length; SPAP the path length on the Y axis; SPML the path length on the X axis; MV mean velocity of the COP in XY axes; MVAP mean velocity of the CoP in the Y axis; MVML mean velocity of the CoP in the X axis; p^ap-value; between baseline and post-KT within each group; p^bp-value between study groups; ES^a effect size (Cohen d) within each group; ES^b effect size (Cohen d) between study groups; p < 0,05; CI confidence interval

ISSN: 2052-1847